Publication:
Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1

Thumbnail Image

relationships.isOrgUnitOf

Program

relationships.isAuthorOf

Author

GÜMÜŞ, MAHMUT

Sezer, A.

Kilickap, S.

ÖZGÜROĞLU, Mustafa

Gogishvili, M.

Turk, H. M.

Cicin, I.

Bentsion, D.

Gladkov, O.

Clingan, P.

Advisor

Date

2021-10-01T00:00:00Z

Language

Type

Article

Publisher

Journal Title

Journal ISSN

Volume Title

Abstract

Description

Source

Keywords

Keywords

Citation

Bondarenko I., Sezer A., Kilickap S., GÜMÜŞ M., ÖZGÜROĞLU M., Gogishvili M., Turk H. M. , Cicin I., Bentsion D., Gladkov O., et al., -Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1-, JOURNAL OF THORACIC ONCOLOGY, cilt.16, sa.10, 2021

URI

http://hdl.handle.net/20.500.12645/29649

Collections

Yayınlar - Eserler

Endorsement

Review

Supplemented By

Referenced By

13

Views

0

Downloads


Sustainable Development Goals